Building Your Care Team
At a Glance
Children with SLC35A2-CDG often need a coordinated team that includes a metabolic geneticist, pediatric epileptologist, genetic counselor, and therapy specialists. Bring genetic, MRI, EEG, and seizure records so clinicians can plan care together.
Because SLC35A2-CDG is an ultra-rare condition that affects multiple systems—especially the brain and metabolism—it cannot be managed by a single doctor. You will need to build a multidisciplinary team, a group of specialists who work together to coordinate your child’s care [1][2].
The Core Medical Team
Your “home base” will typically consist of several main specialists who share care for the most critical aspects of the disease:
- Biochemical Geneticist (Metabolic Specialist): They are the experts in how your child’s body processes sugars. They will:
- Pediatric Epileptologist (Neurologist): While many neurologists treat seizures, an epileptologist specializes in difficult-to-treat cases like those seen in SLC35A2-CDG [4]. They will manage the EEG monitoring, treat infantile spasms, and evaluate if your child has a specific brain malformation called MOGHE that might require surgical consultation [5][6].
- Genetic Counselor: A specialist to discuss family planning, interpretation of genetic testing (including Variant Allele Fractions), and coordinate parental or recurrence-risk testing [1].
- Rehabilitation and Developmental Team: Because of the high risk of hypotonia (low muscle tone) and developmental delays, your child will likely need a team of therapists [2]:
- Physical Therapists (PT): To work on motor skills, head control, and mobility.
- Occupational Therapists (OT): To help with “activities of daily living” and fine motor skills like grasping.
- Speech and Feeding Specialists: Crucial for managing swallowing difficulties and helping your child develop communication tools [3].
Essential Items for Your First Appointment
Rare disease specialists often have long waitlists, so you want to make the most of your first visit. Do not rely entirely on the hospital to send records electronically; bring a physical “care binder” or ensure secure electronic access for:
- The Full Genetic Report: Ensure it includes the Variant Allele Fraction (VAF). This helps the doctor interpret if the mutation is “mosaic” (only in some cells) or present in every cell [5].
- MRI Images: Request secure access or the institution’s preferred DICOM-sharing method. Doctors need to see the actual images of the brain’s white matter and the corpus callosum, not just the written summary from a radiologist [2].
- EEG Reports: Summaries of brain wave patterns, especially if they mention hypsarrhythmia [7].
- A Seizure Diary: A log of what the seizures look like, how long they last, and what time of day they occur. Videos of the movements on your phone can also be incredibly helpful for the doctor.
Vetting Your Doctors
Not every specialist will have heard of SLC35A2-CDG. It is okay to “interview” your doctors to ensure they are the right fit for your family. You might ask:
- “Are you familiar with the use of investigational therapies like D-galactose for CDGs, or are you willing to consult with a national CDG center to manage it?” [3]
- “How do you typically manage drug-resistant epilepsy in children with metabolic disorders?” [4]
- “Do you have experience with MOGHE or other focal brain malformations?” [5]
By gathering the right experts and coming prepared with your child’s data, you move from being a passenger in the medical process to being an active, informed advocate for your child.
Common questions in this guide
Which specialists are usually part of an SLC35A2-CDG care team?
What should I bring to my child's first SLC35A2-CDG specialist visit?
How will doctors monitor D-galactose treatment in SLC35A2-CDG?
When should a child with SLC35A2-CDG see a pediatric epileptologist?
What does a genetic counselor do for a family affected by SLC35A2-CDG?
How can parents help different SLC35A2-CDG specialists work together?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on SLC35A2-CDG.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How often do you manage children with Congenital Disorders of Glycosylation (CDG), and are you comfortable coordinating with other specialists for a rare condition like SLC35A2?
- 2.What is the plan for monitoring my child's labs (like liver enzymes and blood sugar) and growth once we start D-galactose?
- 3.Since transferrin tests can be normal in this condition, what other biomarkers or glycan tests will you use to see if the treatment is working?
- 4.Does my child's EEG or seizure pattern suggest they might have a focal brain malformation like MOGHE that would require specialized surgical evaluation?
- 5.How will you and the neurologist communicate to ensure that seizure medications and metabolic treatments are working together?
References
References (7)
- 1
SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals.
Ng BG, Sosicka P, Agadi S, et al.
Human mutation 2019; (40(7)):908-925 doi:10.1002/humu.23731.
PMID: 30817854 - 2
Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients.
Vals MA, Ashikov A, Ilves P, et al.
Journal of inherited metabolic disease 2019; (42(3)):553-564 doi:10.1002/jimd.12055.
PMID: 30746764 - 3
Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG.
Witters P, Tahata S, Barone R, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2020; (22(6)):1102-1107 doi:10.1038/s41436-020-0767-8.
PMID: 32103184 - 4
SLC35A2-related congenital disorder of glycosylation: Defining the phenotype.
Yates TM, Suri M, Desurkar A, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2018; (22(6)):1095-1102 doi:10.1016/j.ejpn.2018.08.002.
PMID: 30194038 - 5
Frequent SLC35A2 brain mosaicism in mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE).
Bonduelle T, Hartlieb T, Baldassari S, et al.
Acta neuropathologica communications 2021; (9(1)):3 doi:10.1186/s40478-020-01085-3.
PMID: 33407896 - 6
Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE): genetics, mechanisms and precision therapy.
Spyrou J, Lockhart PJ, Maljevic S, et al.
Acta neuropathologica 2026; (152(1)).
PMID: 42542984 - 7
[Clinical characteristics of SLC35A2 gene variants related congenital disorders of glycosylation typeⅡ].
Lang CH, Yang Y, Niu XY, et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; (58(7)):586-590 doi:10.3760/cma.j.cn112140-20200308-00198.
PMID: 32605344
This page is for informational purposes only and does not constitute medical advice. Your child's metabolic, neurology, and rehabilitation clinicians should guide D-galactose therapy, seizure care, testing, and specialist referrals.